• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Geron Announces Publication of Studies Demonstrating Engraftment of Human Embryonic Stem Cell-Derived Cardiomyocytes in the Rodent Heart

Posted on: Thursday, 1 September 2005, 09:01 CDT

Geron Corporation (Nasdaq:GERN) announced today the publication of studies showing that cardiomyocytes differentiated from human embryonic stem cells (hESCs) engraft when transplanted into the rat heart. The results provide proof of concept that transplanted hESC-derived cardiomyocytes survive and retain properties of cardiomyocytes, important for their use in the treatment of heart failure and myocardial infarction.

In the studies reported in the American Journal of Pathology, Dr. Charles Murry and his colleagues at the University of Washington, in collaboration with scientists at Geron Corporation, produced cardiomyocytes from hESCs and injected the cells into the left ventricular wall of normal healthy rats. The transplant was examined one and four weeks after injection and human cells were detected in the rat myocardium at both timepoints. At the four week timepoint, the grafted human cardiomyocytes were identified using characteristic markers including sarcomeric actin, alpha and beta-myosin heavy chain, and myosin light chain 2v. Approximately 10% of the cardiomyocytes at the four week timepoint retained proliferative capacity, thereby potentially enhancing engraftment. Both host and graft derived angiogenesis (new blood vessel formation) was observed, critical to sustaining the viability of the graft. No evidence of tumor formation was seen.

"The successful engraftment of the hESC-derived cardiomyocytes provides evidence for the feasibility of using these cells in myocardial repair," stated Jane S. Lebkowski, Ph.D., Geron's senior vice president of regenerative medicine. "We are currently transplanting these cells in acute and chronic infarct animal models."

Geron is a biopharmaceutical company developing and commercializing three groups of products: i) therapeutic products for oncology that target telomerase; ii) pharmaceuticals that activate telomerase in tissues impacted by senescence, injury or degenerative disease; and iii) cell-based therapies derived from its human embryonic stem cell platform for applications in multiple chronic diseases.

This news release may contain forward-looking statements made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements in this press release regarding potential applications of Geron's technologies constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, need for future capital and maintenance of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in Geron's periodic reports, including the quarterly report on Form 10-Q for the quarter ended June 30, 2005.

Source: Business Wire

More News in this Category